AYTU BIOPHARMA, INC AYTU
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
4/9
Piotroski F — financial health
-8.14
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $66.4M | -$13.6M | $45.8M | -$2.2M | $19.0M |
| 2024 | $65.2M | -$15.8M | $49.1M | -$1.7M | $27.7M |
| 2023 | $107.4M | -$17.1M | $66.6M | — | $39.4M |
| 2022 | $96.7M | -$108.8M | $52.3M | — | $44.3M |
| 2021 | $65.6M | -$58.3M | $29.2M | — | $137.6M |
| 2020 | $27.6M | -$13.6M | $19.4M | -$28.4M | $95.0M |
Recent insider activity (Form 4)
| Insider | Role | Date | Action | Shares | Price |
|---|---|---|---|---|---|
| PYSZCZYMUKA GREG | Chief Commercial Officer | 2025-10-03 | Grant | 12,500 | — |
| Disbrow Jarrett | Chief Business Officer | 2025-10-03 | Grant | 19,606 | — |
| Disbrow Jarrett | Chief Business Officer | 2025-10-03 | Grant | 12,500 | — |
| Selhorn Ryan J | Chief Financial Officer | 2025-10-03 | Grant | 16,243 | — |
| Selhorn Ryan J | Chief Financial Officer | 2025-10-03 | Grant | 17,500 | — |
| Disbrow Joshua R. | Chief Executive Officer | 2025-10-03 | Grant | 31,446 | — |
| Disbrow Joshua R. | Chief Executive Officer | 2025-10-03 | Grant | 22,500 | — |
| LIU VIVIAN H | director | 2025-10-03 | Grant | 10,000 | — |
Why these scores methodology →
Piotroski F-score: 4/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -8.14 (distress)
- Working capital / assets 0.13
- Retained earnings / assets -2.686
- EBIT / assets -0.063
- Equity / liabilities 0.18
Source: SEC EDGAR filings · CIK 0001385818 · as of 2025-06-30. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.